NCI

April 29, 2021

Genetic ancestry and hypertension risk

Racial disparities in hypertension risk are due in part to genetic differences between ancestries, Vanderbilt investigators find in a study of participants in the Million Veteran Program.

By Bill Snyder
April 20, 2021

New therapeutic strategy for leukemia syndrome

Using primary cells from patients with chronic myelomonocytic leukemia, Vanderbilt researchers found synergistic inhibition of cell viability and proliferation, suggesting a new treatment strategy.

By Leigh MacMillan
From left, Kimryn Rathmell, MD, PhD, Bradley Reinfeld, Matthew Madden and Jeffrey Rathmell, PhD, have discovered that immune cells — not cancer cells — are the major glucose consumers in the tumor microenvironment, upending a century-old observation.
April 7, 2021

Study revises understanding of cancer metabolism

Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.

By Leigh MacMillan
Deanna Edwards, PhD, left, Jin Chen, MD, PhD, and colleagues are studying a new therapeutic strategy for triple-negative breast cancer.
April 1, 2021

Breast cancer cells ‘steal’ nutrients from immune cells: study

Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.

By Leigh MacMillan
March 23, 2021

Prostate cancer microenvironment

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.

By Leigh MacMillan
March 9, 2021

Markers for breast cancer progression

Vanderbilt researchers clarify how a microRNA associated with triple-negative breast cancer survival inhibits cancer progression, suggesting new treatment strategies.

By Sarah E. Glass
March 4, 2021

Probiotic protection

A probiotic factor given early in life to mice prevented intestinal inflammation in adulthood, providing a rationale for probiotic intervention in individuals at high risk of developing inflammatory bowel disease.
By Anivarya Kumar
February 4, 2021

Potential biomarker for IBD severity, cancer risk identified

A selenium transport protein produced in the colon may be a novel biomarker for assessing disease severity and cancer risk in patients with inflammatory bowel disease.
By Leigh MacMillan
February 4, 2021

Gene network for leukemia factor

A new method speeds the analysis of factors that control gene expression from days to minutes, allowing researchers to uncover new targets for cancer treatment.
By Leigh MacMillan
January 25, 2021

An interacting factor in leukemia

A blood stem cell protein plays a role in the initiation and progression of leukemia, Vanderbilt researchers have found.
By Anivarya Kumar
January 21, 2021

WIN for blocking cancer growth

William Tansey and colleagues identified proteins that interact with the cancer drug target WDR5 and are important for cancer cell growth.
By Sarah E. Glass
January 7, 2021

Vitamin D activation and cancer risk

Vitamin D protection against colon cancer varies according to parathyroid hormone response, particularly among women.
By Paul Govern
December 17, 2020

Study reveals new strategy for reducing tumor growth, metastasis

A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.
By Leigh MacMillan
1 … 3 4 5 6 7 … 28